Europe Sep 21, 2022 Sophia Genetics Partners With MSK on Clinical Decision Support, Boundless Bio on ecDNA Detection Sep 21, 2022 Propath UK, Nucleai Partner on Spatial Proteomics Panel for Immuno-Oncology Sep 20, 2022 Transcriptomics Plus 'Immune Tolerance' of Normal Tissue Shows Promise in Lung Cancer Prognosis Premium Sep 19, 2022 EMA's CHMP Recommends Gilead's Yescarta for Second-Line Lymphoma Sep 19, 2022 CancerRNA Consortium Will Harness RNA Technology to Enhance Immunotherapies Sep 16, 2022 BMS Combo Immunotherapy Opdualag Approved in Europe for Biomarker-Defined Melanoma Patients Sep 16, 2022 In Brief This Week:Â Precipio, AnHeart Therapeutics, Strata Oncology, Delfi Diagnostics, Incyte Sep 14, 2022 Biomarker Test Access for Precision Oncology Varies Widely in Europe, ESMO Survey Finds Premium Sep 13, 2022 ESMO Data Deepens Understanding of KRAS Inhibitor Activity in Lung, Colorectal Cancer Premium Sep 13, 2022 Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response Sep 13, 2022 Nearly all dMMR Colon Cancer Patients Respond in Trial of Neoadjuvant Opdivo-Yervoy Premium Sep 12, 2022 ESMO Data Sharpens View of How Grail, Exact Sciences Multi-Cancer Early Detection Tests Perform Premium Sep 11, 2022 Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients Premium Sep 11, 2022 Selective Estrogen Receptor Degraders, Modulators Show Promise in ESR1-Mutant Breast Cancer Premium Sep 11, 2022 TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma? Premium Sep 11, 2022 ESMO Study Explores Role of Air Pollution in EGFR-Mutant NSCLC in Non-Smokers Premium Sep 10, 2022 Lynparza Presents Possibility of Cure for Some Patients With Biomarker-Defined Ovarian Cancer Premium Sep 10, 2022 Lilly's Verzenio Extends Five-Year Breast Cancer Survival, Adds to Debate Over Best CDK4/6 Inhibitor Sep 10, 2022 BMS Combo Drug Opdualag Effective in Neoadjuvant NSCLC, But Maybe No Better Than Opdivo Alone Premium Sep 9, 2022 Roche Obtains CE Mark for Ventana PD-L1 Assay as CDx for Libtayo Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
